CHRONIC LYMPHOCYTIC LEUKEMIA

This large, late-stage study is comparing two drug combinations for younger patients with untreated chronic lymphocytic leukemia (CLL). It tests whether adding a third drug, venetoclax, to the standard two-drug combination of ibrutinib and obinutuzumab leads to better disease con…

This study is testing whether combining two cancer drugs, tafasitamab and zanubrutinib, is safe and effective for people newly diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to see if using both drugs together can kill more canc…

This study is testing a combination of four drugs as the first treatment for patients with a specific genetic type of chronic lymphocytic leukemia (CLL). The goal is to see if using these drugs together—a targeted therapy, two chemotherapy drugs, and an immunotherapy—is more effe…

This early-stage study is testing a new combination of two drugs, loncastuximab tesirine and acalabrutinib, for people with chronic lymphocytic leukemia (CLL). The main goal is to find the safest and most effective dose of the loncastuximab drug when added to the standard acalabr…

This early-stage trial is testing a new type of CAR-T cell therapy designed to fight B-cell cancers like leukemia and lymphoma. The therapy modifies a patient's own immune T-cells to hunt and kill cancer cells by targeting two proteins (CD19 and CD20) on the cancer's surface. The…

This study is for adults 65 and older with untreated chronic lymphocytic leukemia (CLL), a type of blood cancer. It compares the standard two-drug treatment (ibrutinib + obinutuzumab) against an experimental three-drug combination that adds a medication called venetoclax. The mai…

This study follows patients who previously received AvenCell's CAR-T cell therapy in earlier clinical trials. Researchers want to understand the long-term safety and effectiveness of these cancer treatments over time. The study will track 178 patients with various blood cancers a…

This study is testing whether adding a new drug called pirtobrutinib to a standard two-drug combination works better for people with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. About 600 participants will be randomly assigned to receive either t…

This study is testing a two-drug combination (pirtobrutinib and venetoclax) for people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The main goal is to see if using a sensitive blood test that detects tiny amounts of leftover c…

This study observes how well the approved drug acalabrutinib works for chronic lymphocytic leukemia patients in real-world French hospital settings. Researchers will follow 350 patients already taking the medication to see how long they stay on it and how it affects their disease…

This trial is testing a stem cell transplant method for people with blood cancers who don't have a perfectly matched donor. It uses stem cells from a partially matched, unrelated donor along with specific medications to prevent complications. The main goal is to see if this appro…

This study aims to find the best COVID-19 booster strategy for people with weakened immune systems, such as those with HIV, organ transplants, or certain cancers. It will compare giving one versus two extra doses of approved mRNA vaccines to see which is safer and builds stronger…

This study is testing a new drug called zilovertamab vedotin (MK-2140) for people with several types of advanced B-cell blood cancers that have come back or stopped responding to other treatments. The main goals are to see if the drug is safe and if it can shrink or eliminate the…

This study is testing a new combination of two oral drugs, duvelisib and venetoclax, for adults with chronic lymphocytic leukemia (CLL) or Richter's syndrome that has come back or stopped responding to prior treatment. The first part of the study aims to find a safe dose when the…

This early-stage trial is testing a new version of CAR-T cell therapy called huCART19-IL18 for adults with certain blood cancers that have returned or not responded to standard treatments. The study aims to find a safe dose and see if the therapy can be reliably manufactured. It …

This is a first-in-human study to test the safety and early effects of a new type of cancer treatment called SC291. It is for adults with certain B-cell blood cancers (like non-Hodgkin lymphoma or chronic lymphocytic leukemia) that have come back or not responded to at least two …

This study is testing if using a lower dose of a standard drug (cyclophosphamide) given after a stem cell transplant can reduce serious infections in the first 100 days. The trial aims to see if this lower dose is just as good at preventing graft-versus-host disease, a common and…

This study is testing whether starting a cancer drug called ibrutinib early, before symptoms appear, can better control high-risk forms of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). It involves 42 patients who have these cancers with specific high-ri…

This study is testing whether a combination of three drugs—acalabrutinib, umbralisib, and ublituximab—can control the growth of chronic lymphocytic leukemia (CLL). It is enrolling adults with CLL, including those whose cancer has come back after treatment and those who have never…

This is an early safety study for people with a type of blood cancer called chronic lymphocytic leukemia (CLL) that has returned or stopped responding to other treatments. It is testing a new drug, AZD6738, given alone and in combination with an existing drug, acalabrutinib. The …

This study is testing whether adding an experimental drug called sonrotoclax to an approved drug, zanubrutinib, works better than zanubrutinib alone for adults newly diagnosed with chronic lymphocytic leukemia (CLL). About 94 participants will be randomly assigned to receive one …

This study is testing whether adding a drug called venetoclax to an existing treatment (ibrutinib) can help patients with chronic lymphocytic leukemia (CLL) whose cancer has become resistant. The goal is to eliminate the genetic changes that cause resistance and better control th…

This early-stage study is testing whether two already-approved leukemia drugs—ibrutinib and obinutuzumab—are safe when given together and in what order. It involves 54 adults whose chronic lymphocytic leukemia has returned or stopped responding to previous treatments. The main go…

This study is testing whether adding a new drug called cirmtuzumab to existing venetoclax treatment can help eliminate remaining cancer cells in people with chronic lymphocytic leukemia. The trial involves patients who have been on venetoclax for at least a year but still show de…

This study is testing if giving a low-dose cancer drug (lenalidomide) along with a standard pneumonia vaccine can help the body's immune system better recognize and attack early-stage chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It enrolled 49 adults wi…

This study is testing whether giving vitamin D supplements to cancer patients who have low vitamin D levels can help improve their survival and delay the need for other treatments. It focuses on people newly diagnosed with certain aggressive lymphomas or a slow-growing type of le…

This is a first-in-human safety study testing a new, experimental CAR-T cell therapy called CAR19.20.22 in adults with B-cell lymphomas that have returned or not responded to at least two prior treatments. The therapy uses the patient's own immune cells, engineered to attack canc…

This study is testing a new drug called IPI-145 in combination with a standard chemotherapy regimen (FCR) for younger adults who have never been treated for chronic lymphocytic leukemia (CLL). The first part aims to find the safest dose, and the second part aims to see how well t…

This study tests whether taking two oral medications together—venetoclax and ibrutinib—can better control chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). It is for adults whose cancer has returned after prior treatment or who have high-risk, untreated dis…

This study is testing an experimental drug called iopofosine I 131 in people with various advanced B-cell blood cancers that have come back or stopped responding to standard treatments. The drug is designed to deliver radiation directly to cancer cells. The main goal is to see if…

This early-stage study is testing the safety and best dose of a new cell therapy called FT819. It is for adults with B-cell cancers like lymphoma or leukemia that have come back or not responded to prior treatments. Researchers are giving FT819 alone or combined with another drug…

This is a very early-stage study to test the safety and find the right dose of a new oral drug called ABBV-453 for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has returned or stopped responding to at least two prior treatments. Particip…

This study is testing a personalized treatment plan for young adults with a hard-to-treat form of chronic lymphocytic leukemia (CLL). All participants start with a two-drug combination. Doctors then check for tiny amounts of leftover cancer cells and adjust the treatment plan. So…

This study is testing a faster, daily schedule for increasing the dose of the drug venetoclax in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to see if this accelerated 5-day schedule is as safe as the standard 5-week schedule,…

This early-stage study is testing the safety and effectiveness of combining two drugs, daratumumab and ibrutinib, for people with chronic lymphocytic leukemia (CLL) who have symptoms but have not yet received any treatment. The goal is to see if using these drugs together works b…

This is an early-stage safety study testing a new type of treatment for patients whose B-cell lymphoma or leukemia has returned or not responded to standard therapies. Doctors take a patient's own immune cells (T cells), genetically modify them in a lab to better recognize and at…

This study allows patients already receiving venetoclax in other trials to continue treatment if they are benefiting and tolerating it well. The main goal is to collect long-term safety information by tracking any side effects. It includes about 165 patients with various blood ca…

This study is testing a specific type of stem cell transplant for patients with various blood cancers. It uses stem cells from a partially matched family donor instead of bone marrow. The main goals are to see how well patients survive and recover, and to learn how the immune sys…

This study is testing a new type of personalized immune cell therapy called rapcabtagene autoleucel (a CAR-T cell therapy) for adults with several aggressive or returning blood cancers. The main goals are to find a safe and effective dose and to see if the therapy can shrink or e…

This study tested a new oral medication called acalabrutinib for adults with chronic lymphocytic leukemia (CLL) and related cancers that have come back or stopped responding to other treatments. The main goals were to find a safe dose and see if the drug could shrink the cancer. …

This study is testing whether a new oral medication called pirtobrutinib works better than standard chemotherapy for people newly diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 309 participants will be randomly assigned to receive eit…

This study is testing a combination of three different drugs (obinutuzumab, ibrutinib, and venetoclax) to treat chronic lymphocytic leukemia (CLL). It aims to find the safest dose and see how well the combination works for patients whose cancer has returned, is resistant to treat…

This study is testing a new oral medication called nemtabrutinib for people with advanced B-cell blood cancers that have come back or stopped responding to other treatments. The main goals are to find a safe and effective dose and to see if the drug can shrink tumors. It is for a…

This study is testing whether adding a newer targeted drug called ibrutinib to a standard chemotherapy combination (FCR) is safe and more effective for younger patients with CLL who have not yet received any treatment. The main goal is to see if this combination can lead to a dee…

This study is testing whether combining three different drugs works better for people with chronic lymphocytic leukemia (CLL) or a more aggressive form called Richter transformation that has returned or hasn't responded to other treatments. The combination includes two immunother…

This study is testing a two-drug combination for people with certain slow-growing types of B-cell lymphoma who have not yet received treatment. The goal is to see how well the pill ixazomib works when given with the antibody drug rituximab to shrink tumors and control the cancer.…

This study is testing whether a new oral medication called nemtabrutinib works better than standard chemoimmunotherapy for people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), which are types of blood cancer. The main goal is to…

This study is testing a combination of two drugs, venetoclax and rituximab, for adults with chronic lymphocytic leukemia (CLL) that has returned or stopped responding to other treatments. The goal is to see how well and how safely this drug pair can control the cancer. Researcher…

This early-stage study is testing whether immune cells from healthy donors, given along with two other drugs, are safe for people with advanced colorectal, stomach, or hard-to-treat blood cancers. The goal is to see if this combination helps the donor immune cells last longer in …

This study is testing a new type of cell therapy for patients with blood cancers or bone marrow diseases who need a stem cell transplant from a partially matched family donor. The goal is to see if adding specially treated immune cells, called 'veto cells,' can help the donor's c…

This study is testing new, potentially safer ways to start treatment with an experimental drug called sonrotoclax for adults with chronic lymphocytic leukemia (CLL). The goal is to find the best schedule for slowly increasing the drug dose at the beginning of treatment to reduce …

This study aims to understand how well patients with chronic lymphocytic leukemia (CLL) stay on the drug acalabrutinib in everyday Italian clinics, outside of controlled trials. It will follow 151 adult patients who started the drug between May 2021 and April 2022. The main goal …

This study tested a drug called acalabrutinib for adults with chronic lymphocytic leukemia (CLL) that had returned or stopped responding to treatment, and who could not tolerate the standard drug ibrutinib. It involved 60 participants and aimed to see if acalabrutinib could shrin…

This study is testing if adding a drug called venetoclax to a standard first-line treatment (a BTK inhibitor) can lead to a very deep and lasting remission in people with chronic lymphocytic leukemia (CLL). The goal is to get the cancer down to such low levels that patients might…

This is an early-stage study to find the safest dose of two cancer drugs, copanlisib and nivolumab, when given together. It is for adults with aggressive blood cancers that have transformed from slower-growing types, like Richter's syndrome. The main goal is to see how well patie…

This study tested whether a newer drug, acalabrutinib, works better than standard drug combinations for adults whose chronic lymphocytic leukemia (CLL) has returned or stopped responding to prior treatment. It directly compared how long patients lived without their cancer getting…

This large study is comparing two different treatment approaches for younger patients with a common type of blood cancer called chronic lymphocytic leukemia (CLL). One group receives a newer, targeted pill (ibrutinib) plus an antibody drug. The other group gets the standard, more…

This study is observing how patients with chronic lymphocytic leukemia (CLL) do on the drug acalabrutinib in real-world Spanish hospitals. It includes about 192 patients who were either starting their first treatment or switching from a similar drug due to side effects. The goal …

This large, international study is testing whether a new oral drug called zanubrutinib works better than the standard combination of bendamustine and rituximab chemotherapy for people newly diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The…

This study compares two targeted drugs, acalabrutinib and ibrutinib, for adults with a hard-to-treat form of chronic lymphocytic leukemia (CLL) who have already had at least one prior therapy. The main goal is to see if acalabrutinib can keep the cancer from getting worse for as …

This study is testing different ways to help people at high risk for cancer or cancer survivors become more active and eat healthier foods. Researchers are comparing methods like weekly phone calls, emails, daily text messages, and online forums to see which combinations work bes…

This study is testing a new approach to prevent a common and dangerous viral infection called CMV in people receiving a stem cell transplant for blood cancer. Researchers are giving a vaccine to the healthy stem cell donors before the transplant. The goal is to see if the donor's…

This study is testing a vaccine designed to prevent cytomegalovirus (CMV) infection in adults with blood cancers who are receiving a half-matched stem cell transplant. CMV is a common virus that can become life-threatening when the immune system is weakened after transplant. The …

This study is testing whether a drug called ruxolitinib can help reduce severe fatigue in people with chronic lymphocytic leukemia (CLL) who are not yet receiving standard anti-cancer therapy. About 10 participants will take the pill twice daily for up to two years. The main goal…

This study is testing whether a structured program of exercise and weight management can help reduce feelings of fatigue in people living with chronic lymphocytic leukemia (CLL). Researchers at MD Anderson Cancer Center are enrolling 30 adult CLL patients to follow a diet and exe…

This study aims to better understand how often two effective leukemia drugs cause high blood pressure and irregular heartbeats. Researchers will give 50 patients smartwatches and home blood pressure monitors to track their heart health during treatment. The goal is to gather real…

This study aims to understand how well the drug acalabrutinib works for chronic lymphocytic leukemia (CLL) in everyday Romanian medical practice, outside of controlled clinical trials. It will follow 250 adult patients who started the drug in 2023 or 2024, collecting their treatm…

This study aims to understand how muscle strength and body composition affect recovery and long-term health in people with blood cancers who receive a stem cell transplant. Researchers will observe 144 patients to see if their muscle health at the time of transplant can predict c…

This study aims to find a more precise blood test to predict which patients with chronic lymphocytic leukemia or multiple myeloma are at highest risk for getting infections. Researchers will analyze blood samples from about 150 adults with these cancers over two years, looking fo…

This study observes how patients with chronic lymphocytic leukemia (CLL) respond to the drug acalabrutinib during routine treatment in Russian hospitals. Researchers will track 90 adult patients who recently started this medication to understand how well it works and what side ef…

This study aims to understand why some families have a higher risk of developing blood and lymph node cancers like leukemia and lymphoma. Researchers are observing and collecting health information from families with a history of these cancers to identify genetic and environmenta…

This observational study aims to understand how doctors in Russia treat chronic lymphocytic leukemia (CLL) in real-world settings. Researchers will collect data from approximately 6,000 adult patients over two years, tracking their treatment choices and disease characteristics. T…